RhumbLine Advisers’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $642K | Buy |
207,805
+7,048
| +4% | +$21.8K | ﹤0.01% | 2513 |
|
|
2025
Q1 | $701K | Buy |
200,757
+12,159
| +6% | +$42.4K | ﹤0.01% | 2351 |
|
|
2024
Q4 | $617K | Buy |
188,598
+10,724
| +6% | +$35.1K | ﹤0.01% | 2532 |
|
|
2024
Q3 | $685K | Sell |
177,874
-7,193
| -4% | -$27.7K | ﹤0.01% | 2497 |
|
|
2024
Q2 | $572K | Buy |
185,067
+14,607
| +9% | +$45.1K | ﹤0.01% | 2574 |
|
|
2024
Q1 | $440K | Buy |
170,460
+5,836
| +4% | +$15.1K | ﹤0.01% | 2744 |
|
|
2023
Q4 | $412K | Sell |
164,624
-3,608
| -2% | -$9.02K | ﹤0.01% | 2780 |
|
|
2023
Q3 | $342K | Buy |
168,232
+2,415
| +1% | +$4.9K | ﹤0.01% | 2856 |
|
|
2023
Q2 | $381K | Buy |
165,817
+6,690
| +4% | +$15.4K | ﹤0.01% | 2864 |
|
|
2023
Q1 | $482K | Buy |
159,127
+9,592
| +6% | +$29.1K | ﹤0.01% | 2449 |
|
|
2022
Q4 | $348K | Buy |
149,535
+6,695
| +5% | +$15.6K | ﹤0.01% | 2614 |
|
|
2022
Q3 | $273K | Buy |
142,840
+7,916
| +6% | +$15.1K | ﹤0.01% | 2755 |
|
|
2022
Q2 | $366K | Buy |
134,924
+31,146
| +30% | +$84.5K | ﹤0.01% | 2648 |
|
|
2022
Q1 | $309K | Buy |
103,778
+13,243
| +15% | +$39.4K | ﹤0.01% | 2637 |
|
|
2021
Q4 | $352K | Buy |
90,535
+71
| +0.1% | +$276 | ﹤0.01% | 2652 |
|
|
2021
Q3 | $388K | Buy |
90,464
+2,546
| +3% | +$10.9K | ﹤0.01% | 2665 |
|
|
2021
Q2 | $266K | Buy |
+87,918
| New | +$266K | ﹤0.01% | 2830 |
|
|
2019
Q2 | – | Sell |
-48,597
| Closed | -$174K | – | 2967 |
|
|
2019
Q1 | $174K | Sell |
48,597
-435
| -0.9% | -$1.56K | ﹤0.01% | 2776 |
|
|
2018
Q4 | $188K | Buy |
49,032
+15,416
| +46% | +$59.1K | ﹤0.01% | 2754 |
|
|
2018
Q3 | $318K | Buy |
33,616
+260
| +0.8% | +$2.46K | ﹤0.01% | 2487 |
|
|
2018
Q2 | $243K | Buy |
+33,356
| New | +$243K | ﹤0.01% | 2640 |
|